PRECISION BIOSCIENCES INC
For the period ended May 27, 2026. Filed May 27, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 27, 2026 · Filed May 27, 2026
Contents
EX-99.1 · Next Steps
Next Steps
The next steps for the ELIMINATE-B trial are to treat more patients under current cohorts in Part 1 of the trial increasing the size and strength of the data set. Precision expects to collect additional biopsy data to support the direct targeting and elimination of cccDNA. Precision is working with global investigators to create the future framework for nucleoside analog withdrawal and expansion into Part 2 of the ELIMINATE-B trial. The current and future dataset is expected to inform selection of the optimal dosing schedule for Part 2 expansion. Precision expects to provide additional updates on the ELIMINATE-B trial by the end of 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.